
Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, announced two presentations …
Read More